Recently, relevant state departments have conducted a survey on medical export products in the latest quarter. The data show that the results are not optimistic, with a total increase of 20% year-on-year, but the medical device industry has continued to maintain its momentum; among them, the pharmaceutical industry's production and sales rate is 96.2%. The pharmaceutical industry's production and sales rate was 95.6%, down 1.3 percentage points from March. Compared with the decline of the first quarter, the situation in April did not change much, especially the export growth and efficiency growth continued the unfavorable situation in the first quarter. Every manufacturer has begun to study the corresponding strategy. If medical equipment still wants to maintain this momentum, innovation is a must.
The export of APIs is still not ideal
The data shows that in the first quarter, the pharmaceutical industry realized an export delivery value of 32.33 billion yuan, a year-on-year increase of 6.6%, which was lower than the annual growth rate of nearly 10 percentage points last year. The export growth of chemical raw materials and medical devices, which accounted for a large proportion of total exports, stagnated, with a year-on-year increase of only 2.4% and a decrease of 1.3%. From January to April, the export value of APIs was 1.982 billion, down 0.65% year-on-year. Although the total export volume of medical devices has maintained a positive growth, there has also been a 6.07% decline in medical accessories.
Affected by the international macro economy, China's chemical raw materials continued the decline in export growth in 2011.
In 2011, China's API exports underwent certain pressures under the European and American debt crisis. Customs statistics show that the 75 chemical raw materials and preparations that were tracked in 2011, compared with the same period of last year, the export volume of raw materials decreased by 5%. Among the 65 key chemical drug export varieties that were tracked, about 40% of the varieties exported decreased.
Rong Hao, deputy director of the Western Medicine Department of the China Chamber of Commerce for Import and Export of Medicines and Health Products, told the Shanghai Securities News that although the growth rate of chemical raw materials exports is slowing, it still maintains positive growth, mainly due to the economic downturn in Europe and the United States. "The main export market for chemical raw materials in China is Europe and the United States. Under the background of their monetary tightening, the depreciation of the euro, the decline in purchasing intentions, and insufficient replenishment of stocks, the growth rate of API exports has declined."
At the same time, industry experts pointed out that the raw material medicine industry is currently facing more challenges than opportunities, and finding the varieties that are suitable for international market expansion and have sustainable development advantages has become the key to the breakthrough of API companies. The development of high value-added small varieties and new demand markets, and further improvement of environmental protection processes, will be the direction of the transformation of API manufacturing enterprises.
“At present, the upgrading trend of the raw material medicine industry is obvious.†In Rong Rong’s view, the raw material medicine enterprises have extended to the downstream of the industrial chain. "For example, in the past few years, our penicillin exports were mainly penicillin industrial salts, and recently we have transferred to intermediates 6APA, cephalosporin preparations, etc."
Benefit growth continues to decline
The medical industry benefit data for the first two months announced during the same period is also not optimistic. In the first two months of this year, the pharmaceutical industry realized a main business income of 229.16 billion yuan, a year-on-year increase of 21.4%; total profit of 21.1 billion yuan, an increase of 11.4%, lower than last year's annual growth rate of 12 percentage points; sales revenue margin of 9.2%, Decrease by 0.8 percentage points year-on-year. The decline in profit growth was mainly due to the significant decline in the benefits of chemical drugs and preparations. In the first two months, the profit rate of sales of chemical raw materials decreased by 2.1 percentage points year-on-year, and the profit decreased by 18.4% year-on-year; the profit margin of sales of C-arm chemical products decreased by 1.7 percentage points year-on-year, and the profit only increased by 2.2% year-on-year. Other industry profits increased by more than 20%.
From the quarterly report of pharmaceutical companies, the profit growth rate is indeed declining. Wind's statistics show that the industry's profit growth rate continued to decline in the first quarter of 2012. Operating income increased by 20.65% year-on-year; net profit realized by 2.65% year-on-year, significantly lower than the growth rate of the same period last year. In the sub-industry, the bio-products industry rebounded significantly, the profit growth rate improved significantly, the gross profit margin and net profit margin also increased, and the growth rate of the other sub-sectors showed different degrees of decline.
Our bath and shower time is cherished and often the start or end to a great day. Having a seat while showering or bathing can keep you safe, comfortable and independent. Bathe Independently with NOVA`s full line of Bath and Shower Benches, Stools and Accessories. Don`t forget your 84″ Hand Held Shower- it`s a must!
Shower Chair,Shower Chair With Arms And Back,Bath Chair For Elderly,Hospital Bathing Chair,Shower Chair With Wheels
jinan Fangqi Sunshine education consulting CO.,LTD. , https://www.fzrehabmarket.com